Concordance of p53 Immunohistochemistry and TP53 Mutation Status in Endometrial Cancer

被引：0

作者：

Paula, Arnaud Da Cruz ^{[1
]}

DeLair, Deborah ^{[2
]}

Fix, Daniel ^{[3
]}

Soslow, Robert ^{[1
]}

Park, Kay ^{[1
]}

Chiang, Sarah ^{[1
]}

Reis-Filho, Jorge ^{[1
]}

Zehir, Ahmet ^{[1
]}

Murali, Rajmohan ^{[1
]}

Makker, Vicky ^{[1
]}

Cadoo, Karen ^{[1
]}

Mueller, Jennifer ^{[1
]}

Leitao, Mario ^{[1
]}

Abu-Rustum, Nadeem ^{[1
]}

Aghajanian, Carol ^{[1
]}

Weigelt, Britta ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] NYU Langone Med Ctr, New York, NY USA

[3] Hackensack Univ Med Ctr, Hackensack, NJ USA

来源：

MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

1080

引用

页码：1034 / 1035

页数：2

共 50 条

[21] p53 immunohistochemical staining and correlation with TP53 status
Viana-Errasti, J.
Martinez Aracil, A. P.
Jimenez, K.
Pereda, A.
Perez de Nanclares, G.
Aguirre, J. J.
[J]. VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S137 - S138
[22] p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
Boldrin, Elisa
Piano, Maria Assunta
Bernaudo, Francesco
Alfieri, Rita
Biasin, Maria Raffaella
Montagner, Isabella Monia
Volpato, Alice
Mattara, Genny
Lamacchia, Francesco
Magni, Giovanna
Rosato, Antonio
Scapinello, Antonio
Pilati, Pierluigi
Curtarello, Matteo
[J]. CANCERS, 2023, 15 (10)
[23] P53 immunohistochemistry does not correlate with mutation status and should not be used as a screening tool for TP53 mutations in myeloid malignancies
Karner, Kristin
Tripp, Sheryl R.
Kohan, Jessica
Salama, Mohamed
[J]. MODERN PATHOLOGY, 2018, 31 : 527 - 527
[24] P53 immunohistochemistry does not correlate with mutation status and should not be used as a screening tool for TP53 mutations in myeloid malignancies
Karner, Kristin
Tripp, Sheryl R.
Kohan, Jessica
Salama, Mohamed
[J]. LABORATORY INVESTIGATION, 2018, 98 : 527 - 527
[25] TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
Ruzinova, Marianna B.
Lee, Yi-Shan
Duncavage, Eric J.
Welch, John S.
[J]. HAEMATOLOGICA, 2019, 104 (08) : E345 - E348
[26] TP53 gene and p53 protein vs. endometrial carcinoma
Zajac, Agnieszka
Stachowiak, Grzegorz
Stetkiewicz, Tomasz
Wilczynski, Jacek R.
[J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (03): : 228 - 230
[27] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
Jiang, A.
Qi, C.
Chang, H.
[J]. MODERN PATHOLOGY, 2009, 22 : 269A - 269A
[28] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
Jiang, A.
Qi, C.
Chang, H.
[J]. LABORATORY INVESTIGATION, 2009, 89 : 269A - 269A
[29] Performance of p53 Immunohistochemistry as a Surrogate Marker for TP53 Mutations in the PORTEC-3 Endometrial Carcinoma Cohort
Leon-Castillo, Alicia
Vermij, Lisa
de Boer, Stephanie
Singh, Naveena
Fyles, Anthony
Mclachlin, C. Meg
Leary, Alexandra
Nijman, Hans
Smit, Vincent
Nout, Remi
Horeweg, Nanda
Creutzberg, Carien
Bosse, Tjalling
[J]. MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 710 - 711
[30] Performance of p53 Immunohistochemistry as a Surrogate Marker for TP53 Mutations in the PORTEC-3 Endometrial Carcinoma Cohort
Leon-Castillo, Alicia
Vermij, Lisa
de Boer, Stephanie
Singh, Naveena
Fyles, Anthony
Mclachlin, C. Meg
Leary, Alexandra
Nijman, Hans
Smit, Vincent
Nout, Remi
Horeweg, Nanda
Creutzberg, Carien
Bosse, Tjalling
[J]. LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 710 - 711

← 1 2 3 4 5 →